Cardiogen
Cardiogen (Ala-Glu-Asp-Arg) is a synthetic Khavinson bioregulator peptide marketed for cardiovascular and myocardial support. Evidence is limited to preclinical work and Russian reports from the originating group, without independent human trials.
01 Overview
Cardiogen is a tetrapeptide bioregulator claimed to target heart tissue, derived from the developer's work on organ-specific peptide extracts (e.g., the cardiac extract used in the registered product). Animal and cell studies from the group report myocardial protective and regenerative effects.\n\nThere are no independent controlled human trials. Cardiovascular disease demands medical care, so self-use of an unproven peptide is high-risk. Sold as a research peptide.
02 Mechanism
Proposed tissue-specific regulation of cardiomyocyte gene expression, supporting repair and function; unverified in humans.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Anecdotal | 5–10 mg/day | IM | Short cycled courses per vendor protocols; no clinical basis. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Myocardial supportReported cardioprotective effects in animal/cell models. | n/a | Preclinical | |
| Cardiovascular anti-aging claimMarketed for heart aging; unverified in humans. | n/a | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Delay of appropriate cardiac careRelying on an unproven peptide for heart symptoms risks delaying life-saving treatment. | Severe | Situational | Unconfirmed | |
| Injection-site reactionLocal irritation at injection sites. | Mild | Common | Anecdotal |